- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00690521
A Comparison of Hydrochlorothiazide and Metolazone in Combination With Furosemide in Congestive Heart Failure Patients
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Objective: To establish which combination of diuretics is the most effective in promoting diuresis in congestive heart failure patients. Secondary Objectives: To determine the duration of action of furosemide as monotherapy and in combination with either hydrochlorothiazide or metolazone. To determine the effect of diuretic combination therapy on neurohormonal activation. Background: Diuretic resistance occurs when a potent diuretic drug, such as furosemide, is given in therapeutic doses and fails to reduce extracellular fluid volume to the desired level in an edematous patient. Studies have shown that metolazone and hydrochlorothiazide have demonstrated a synergistic response when used in combination with furosemide in congestive heart failure patients. The current guidelines for treating diuretic resistance in congestive heart failure patients recommend the metolazone-furosemide combination. However, there is no evidence to conclude that this combination is superior to hydrochlorothiazide-furosemide in increasing diuresis. Methods: Randomized, double-blind, crossover study to compare the efficacy of hydrochlorothiazide and metolazone in combination with stable doses of furosemide in 13 patients with congestive heart failure. The primary endpoint will be change in urinary output. Secondary endpoints will be changes in weight, neurohormones (angiotensin II, catecholamines, brain natriuretic peptide, aldosterone), and electrocardiographic parameters of ventricular instability. Study procedures will be performed at the UNM General Clinical Research Center. Patients will be hospitalized for 2 separate 4-day admissions, separated by a 1-week washout period. At each admission each patient will receive furosemide in combination with either metolazone or hydrochlorothiazide (metolazone for one admission and hydrochlorothiazide for the other). Following administration of combination therapy, blood and urine samples will be collected throughout the day to chart the onset and magnitude of effect of each treatment regimen. Various hemodynamic, renal, endocrine, and neurohormonal parameters will be assesed as will the effect of each combination treatment on ventricular instability using 12-lead electrocardiography. Data will be analyzed using ANOVA to compare changes from baseline and the Student t-test to analyze intertreatment differences.
All statistical analysis will be performed using SAS v6.12.
Study Type
Enrollment (Anticipated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Joe R. Anderson, PharmD
- Phone Number: 505-272-3664
- Email: janderson@salud.unm.edu
Study Contact Backup
- Name: James J Nawarskas, PharmD
- Phone Number: 505-272-0584
- Email: jnawarskas@salud.unm.edu
Study Locations
-
-
New Mexico
-
Albququerque, New Mexico, United States, 87120
- Recruiting
- University of New Mexico Hospital
-
Contact:
- Joe R. Anderson, PharmD
- Phone Number: 505-272-3664
- Email: janderson@salud.unm.edu
-
Contact:
- James J. Nawarskas, PharmD
- Phone Number: 505-272-0584
- Email: jnawarskas@salud.unm.edu
-
Principal Investigator:
- Joe R. Anderson, PharmD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age >18 years
- Diagnosis of chronic congestive heart failure with an ejection fraction ≤45%
- Currently on a stable regimen of furosemide consisting of a daily dose of at least 80 mg for at least two weeks.
- Patients receiving ACE-inhibitors and/or beta-blockers must be taking these medications for at least two weeks in stable doses.
Exclusion Criteria:
- Renal dysfunction (serum creatinine >2 mg/dl or creatinine clearance of <30 ml/min as calculated by the Cockroft and Gault equation)
- Hepatic dysfunction (AST and ALT >3 times the upper limit of the normal)
- Hypokalemia (<4.0 mg/dl)
- Concomitant treatment with any diuretic other than furosemide (with the exception of spironolactone).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: 1
Patients will be randomized to receive either metolazone or HCTZ in a randomized, double-blind, placebo controlled crossover trial.
The patients will receive the alternative medication if The specific dose of hydrochlorothiazide will be determined by the individual's creatinine clearance.
A creatinine clearance of 30-50 mL/min will indicate a dose of 50 mg per day.
A creatinine clearance of > 50 mL/min will indicate a dose of 25 mg per day.5
If metolazone is added to their regimen, the specific dose will be determined using the equivalence ratio of 5 mg metolazone to 50 mg hydrochlorothiazide.
|
The specific dose of hydrochlorothiazide will be determined by the individual's creatinine clearance.
A creatinine clearance of 30-50 mL/min will indicate a dose of 50 mg per day.
A creatinine clearance of > 50 mL/min will indicate a dose of 25 mg per day.5
If metolazone is added to their regimen, the specific dose will be determined using the equivalence ratio of 5 mg metolazone to 50 mg hydrochlorothiazide.
|
Active Comparator: 2
Patients will be randomized to receive either metolazone or HCTZ in a randomized, double-blind, placebo controlled crossover trial.
The patients will receive the alternative medication if The specific dose of hydrochlorothiazide will be determined by the individual's creatinine clearance.
A creatinine clearance of 30-50 mL/min will indicate a dose of 50 mg per day.
A creatinine clearance of > 50 mL/min will indicate a dose of 25 mg per day.5
If metolazone is added to their regimen, the specific dose will be determined using the equivalence ratio of 5 mg metolazone to 50 mg hydrochlorothiazide.
|
The specific dose of hydrochlorothiazide will be determined by the individual's creatinine clearance.
A creatinine clearance of 30-50 mL/min will indicate a dose of 50 mg per day.
A creatinine clearance of > 50 mL/min will indicate a dose of 25 mg per day.5
If metolazone is added to their regimen, the specific dose will be determined using the equivalence ratio of 5 mg metolazone to 50 mg hydrochlorothiazide.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The primary endpoint will be change in urinary output.
Time Frame: 4 days
|
4 days
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Secondary endpoints will be changes in weight, neurohormones (angiotensin II, catecholamines, brain natriuretic peptide, aldosterone), and electrocardiographic parameters of ventricular instability.
Time Frame: 4 days
|
4 days
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- HRRC 03-477
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Congestive Heart Failure
-
Echosense Ltd.WithdrawnCongestive Heart Failure (CHF)United States
-
Corthera, Inc.(formerly BAS Medical, Inc.), a member...TerminatedCongestive Heart Failure (CHF)Russian Federation
-
Meir Medical CenterUnknown
-
Adnan Kastrati, MDBiotronik SE & Co. KGCompleted
-
Signature Medical, Inc.WithdrawnHeart Failure,Congestive
-
Nihon KohdenTerminatedHeart Failure,CongestiveUnited States
-
ELA Medical, Inc.Approved for marketing
-
Abbott Medical DevicesCompletedCongestive Heart Failure TreatedItaly
-
Echosense Ltd.Terminated
-
Magenta Medical Ltd.TerminatedCongestive Heart Failure | Heart Failure, Congestive | Acute Heart FailureCroatia, Belgium, Serbia
Clinical Trials on metolazone or hydrochlorothiazide
-
Sir Mortimer B. Davis - Jewish General HospitalNovartis PharmaceuticalsWithdrawnHypertension | DiabetesCanada
-
NHS Greater Glasgow and ClydeUniversity of GlasgowActive, not recruitingHeart FailureUnited Kingdom
-
Boryung Pharmaceutical Co., LtdCompletedThe Elderly (≥ 70 Years) With Essential HypertensionKorea, Republic of
-
Mylan Pharmaceuticals IncCompleted
-
Yonsei UniversityWithdrawn
-
Yonsei UniversityWithdrawn
-
Mylan Pharmaceuticals IncCompleted
-
Aultman Health FoundationTerminatedAcute Decompensated Heart FailureUnited States
-
Scripps HealthWithdrawnAcute Decompensated Heart FailureUnited States